BridgeBio Pharma, Inc.BBIONASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank88
3Y CAGR+6.1%
5Y CAGR+7.2%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+6.1%/yr
vs +30.0%/yr prior
5Y CAGR
+7.2%/yr
Consistent
Acceleration
-23.8pp
Decelerating
Percentile
P88
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive declineStrong
PeriodValueYoY Change
TTM$477.54M-5.7%
2024$506.46M+11.1%
2023$455.71M+14.1%
2022$399.46M-11.4%
2021$451.02M+33.8%
2020$337.05M+60.5%
2019$209.95M+49.9%
2018$140.07M+358.4%
2017$30.56M-